WO2000061593A1 - Derives d'erythromycine - Google Patents
Derives d'erythromycine Download PDFInfo
- Publication number
- WO2000061593A1 WO2000061593A1 PCT/JP2000/002226 JP0002226W WO0061593A1 WO 2000061593 A1 WO2000061593 A1 WO 2000061593A1 JP 0002226 W JP0002226 W JP 0002226W WO 0061593 A1 WO0061593 A1 WO 0061593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- compound
- represented
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Definitions
- the present invention relates to a novel erythromycin derivative or a salt thereof having an excellent antibacterial activity as an antibacterial agent, particularly against atypical mycobacteria including multidrug-resistant bacteria, and a medicament containing them as an active ingredient .
- Atypical mycobacterial infections are extremely intractable diseases because atypical mycobacteria are less sensitive to various antibacterial agents, including antituberculous agents.
- Examples of the compound having a similar indication to the compound of the present invention include rifampicin [rifa imicin; The 'Merck' Index (The Merck Index), 12th edition, 8382] and the like.
- Clarithromycin is a macrolide derivative having a chemical structure.
- HIV human immunodeficiency virus
- cancer Increase in susceptible individuals with impaired defense mechanisms in the body, such as patients, diabetic patients, and the elderly; increase in multidrug-resistant bacteria represented by methicillin-resistant Staphylococcus aureus; Alternatively, there are cases of bacterial alternation of patients caused by these bacteria, and these factors make chemotherapy for opportunistic infections more difficult.
- Atypical mycobacteria the causative organism of this infection, have a slow growth rate and survive in phagocytic cells for a long period of time even if they are saturated. is necessary.
- MA C Mycobacterium avium co lex
- surgical treatment is currently being considered to treat this infection.
- clarithromycin described above lacks selectivity for atypical mycobacteria, and clarithromycin-resistant MAC is already known.
- chemotherapy for atypical mycobacterial infections has various effects, such as poor sensitivity to existing antibacterial agents, or an environment in which microbial alterations or resistant bacteria are likely to appear. There is a problem. Disclosure of the invention
- An object of the present invention is to provide a compound which is selective for atypical mycobacteria and has excellent antibacterial activity.
- the present inventors have conducted intensive studies to solve the above-mentioned problems.
- the novel erythromycin derivative or its salt according to the present invention is useful as an antibacterial agent, and is particularly excellent against atypical mycobacteria.
- the present invention was found to be a compound having an antibacterial activity.
- R represents a hydrogen atom or a lower alkyl group
- R 1 is an alkyl group having 5 to 12 carbon atoms which may have a substituent
- R 4 represents an optionally substituted alkyl group Group, alkoxyalkyl group which may have a substituent, alkylthioalkyl group which may have a substituent, alkylaminoalkyl group which may have a substituent, aryl group which may have a substituent or even represent an Ararukiru group substituted
- R 5 is
- a medicament comprising as an active ingredient a compound represented by the above general formulas (I) and ( ⁇ ) or a physiologically acceptable salt thereof.
- the medicament provided by the present invention can be suitably used, for example, as an antibacterial agent, particularly a therapeutic agent for atypical mycobacterial infection.
- examples of the lower alkyl group represented by R include a methyl group, an ethyl group, an n-propyl group, and an n-butyl group.
- the alkyl group of the alkyl group having 5 to 12 carbon atoms which may have a substituent represented by R 1 is Represents a linear or branched alkyl group having 5 to 12 carbon atoms, for example, n-pentyl group, isopentyl group, neopentyl group, tert-pentyl group, n-hexyl group, 4-methylpentyl group , N-heptyl, n-octyl, II-nonyl, n-decyl, n-undecyl, n-dodecyl and the like.
- the cycloalkyl group of the optionally substituted cycloalkyl group represented by R 1 represents a cycloalkyl group having 3 to 6 carbon atoms, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl
- the (cycloalkyl) alkyl group of the (cycloalkyl) alkyl group which may have a substituent represented by R 1 is a straight-chain or branched-chain having 1 to 12 carbon atoms.
- the aralkyl group of the aralkyl group which may have a substituent represented by R 1 , R 4 or R 5 is a linear or branched aralkyl group having 1 to 12 carbon atoms.
- the acyl group of the optionally substituted acyl group represented by R 3 may be any position of a formyl group, an alkyl group, a cycloalkyl group, a (cycloalkyl) alkyl group, an aryl group or an aralkyl group.
- the alkyl group of the alkyl group which may have a substituent represented by R 4 , R 5 or ⁇ ⁇ represents a linear or branched alkyl group having 1 to 12 carbon atoms, for example, a methyl group , Ethyl, ⁇ -propyl, isopropyl, ⁇ -butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-to Examples include a xyl group, an n-heptyl group, a ⁇ -octyl group, an n-nonyl group, an n-decyl group, an n-pentadecyl group, and an n-dodecyl group.
- the alkoxyalkyl group of the alkoxyalkyl group which may have a substituent represented by R 4 is a straight-chain or branched alkyl group having 1 to 12 carbon atoms and a straight-chain or branched alkyl group having 1 to 12 carbon atoms.
- a substituted or branched alkoxy group at any position for example, methoxymethyl group, ethoxymethyl group, n-propoxymethyl group, isopropoxymethyl group, n-butoxymethyl group, isobutoxy group Methyl, sec-butoxymethyl, tert-butoxymethyl, n-pentyloxymethyl, isopentyloxymethyl, neopentyloxymethyl, tert-pentyloxymethyl, n-hexyl Xymethyl group, n-heptyloxymethyl group, ⁇ -octyloxymethyl group, n-nonyloxymethyl group, n-decyloxymethyl group, ⁇ -dendecyloxymethyl group, n-dodecyloxy Cimethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, methoxyheptyl, methoxyoctyl,
- Preferred aryl groups include, for example, phenyl, naphthyl, pyridyl, pyrimidyl, birazinyl, furyl, benzofuranyl, chenyl, benzo [b] thenyl, pyrrolyl, indolyl, imidazolyl. , Benzimidazolyl, quinolyl, and isoquinolyl groups.
- any functional group may be used as long as the group can be substituted.
- the number and types of the substituents are not particularly limited. When two or more substituents are present, they may be the same or different, and the substitution position is not particularly limited. Examples of the substitutable group include a hydroxyl group which may have a protecting group, an alkoxy group, an amino group which may have a substituent, a labamoyl group which may have a substituent, a halogen atom, and an alkyl group.
- the protecting group for the hydroxyl group may be any that is substantially inert in a system where the hydroxyl group should not participate in the reaction and can be easily cleaved under the conditions of the specific deprotection reaction. Examples thereof include an acyl group, a trialkylsilyl group such as a trimethylsilyl group and a tribenzylsilyl group, and a benzyl group.
- the alkoxy group represents a linear or branched alkoxy group, such as methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, n-hexyloxy and the like.
- amino group which may have a substituent examples include an amino group, a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, an n-butylamino group, an isobutylamino group, a sec-butylamino group, and a tert-butylamino group.
- Luba Moyl groups include, for example, carbamoyl, N-methylcarbamoyl, N_ethylcarbamoyl, N-n-propyl carbamoyl, N-isopropylcarbamoyl, N-n-butylcarbamoyl, N— N-sec-butylcarbamoyl group, N-tert-butylcarbamoyl group, N_n-pentyl carbamoyl group, N— ⁇ ⁇ sopentylcarbamoyl group, N—neopentylcarbamoyl group, N— tert-pentylcarbamoyl group, Nn-hexylcarbamoyl group, N, N-dimethylcarbamoyl group, N, N-getylcarbamoyl group, and the like.
- halogen atom examples include a fluorine atom, a chlorine atom, and bromine.
- atom or iodine atom examples include aryloxy groups such as phenoxy, naphthyloxy, and pyridyloxy.
- Group, Pirimijiruokishi group, Birajiniruokishi group, benzo Furaniruokishi group, Cheniruokishi group, Indoriruokishi group, benzimidazolinyl Ruokishi group, Kinoriruokishi group, etc. isoquinolyloxy O alkoxy group.
- alkoxycarbonyl group examples include a methoxycarbonyl group, an ethoxycarbonyl group, an n-propoxycarbonyl group, an isopropoxycarbonyl group, an n-butoxycarbonyl group, an isobutoxycarbonyl group, and a sec-butoxycarbonyl group.
- n-pentyloxycarbonyl group isopentyloxycarbonyl group, neopentyloxycarbonyl group, tert-pentyloxycarbonyl group, n-hexyloxycarbonyl group and the like.
- the aryloxycarbonyl group includes, for example, phenoxycarbonyl, naphthyloxycarbonyl, pyridyloxycarbonyl, pyrimidyloxycarbonyl, benzofuranyloxycarbonyl, chenyloxy Xycarbonyl group, indolyloxycarbonyl , Benzimidazolyloxycarbonyl group, quinolyloxycarbonyl group, isoquinolyloxycarbonyl group and the like.
- aralkyloxycarbonyl group examples include benzyloxycarbonyl group, naphthylmethyloxycarbonyl group, Pyridylmethyloxycarbonyl group, furylmethyloxycarbonyl group, benzofuranylmethyloxycarbonyl group, tenyloxycarbonyl group, indolylmethyloxycarbonyl group, imidazolylmethyloxycarbonyl group, benzoimi Examples thereof include a dazolylmethyloxycarbonyl group, a quinolylmethyloxycarbonyl group, and an isoquinolylmethyloxycarbonyl group.
- the above-mentioned substitutable alkyl group, acyl group, cycloalkyl group and aryl group include, for example, the groups exemplified above.
- the “aryl group” in the “aralkyl group”, the “aryl group”, the “aryl group”, the “aryloxy group”, the “aryloxycarbonyl group”, and the “aralkyloxycarbonyl group” May be any position in the ring constituent as long as it is an element capable of substitution Z bond.
- the compound of the present invention represented by the above general formula (I) has an asymmetric carbon and may exist in stereoisomers such as optical isomers, diastereoisomers, and geometric isomers. And any mixtures or racemates thereof and salts thereof are also included in the scope of the present invention.
- the compound of the present invention represented by the general formula (I) can be converted into a salt, preferably a physiologically acceptable salt, if desired, and can be converted from the produced salt into a compound in a free form.
- a salt of the compound represented by the general formula (I) of the present invention include an acid addition salt and an alkali addition salt.
- the acid addition salt include hydrochloride, hydrobromide, nitrate, and sulfate.
- Mineral acid salts such as salts, hydroiodide salts and phosphates, acetates, propionates, butyrate, isobutyrate, formate, valerate, isovalerate, pivalate, trifluoroacetate, Acrylate, maleate, tartrate, citrate, oleate, laurate, stearate, myristate, succinate, lactobionate, daltarate, sebacate, dalcone Acid salt, benzoate, methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, phthalate, terephthalate, citrate, P-toluene Sulfonate, lauryl sulfate, darcebutate, malate, malonate, aspartate, glutamate, adipate, oxalate, nicotinate, picrate, thiocyanate, pendecanoate
- the compound of the present invention represented by the general formula (I) or a salt thereof may exist as an arbitrary crystal form depending on production conditions, or as a solvate of any water or organic solvent. Crystal forms, hydrates, solvates and mixtures thereof are also included in the scope of the present invention.
- Preferred compounds of the present invention include the compounds described below, but the present invention is not limited thereto.
- Me is a methyl group
- Et is an ethyl group
- n-Pr is an n-propyl group
- i-Pr is an isopropyl group
- n-Bu is an n-butyl group
- i-Bu is an isobutyl group
- s -Bu is sec-butyl group
- t-Bu is tert-butyl group
- n-Pent is n-pentyl group
- i-Pent is isopentyl group
- neo-Pent is neopentyl group
- t-Pent is tert-pentyl group
- n -Hex is n-hexyl group
- n-Hept is n-heptyl group
- n-Oct is n-octyl group
- novel erythromycin derivative represented by the general formula U) of the present invention can be produced, for example, by the following method, but the production method of the compound of the present invention is not limited to these methods.
- Examples of the base used in the present production method include, for example, triethylamine, pyridine, N, N-diisopropylethylamine, 4-dimethylaminopyridine, 1,8-diazabicyclo [5.4.0] —7— Organic bases such as pendecene, 1, 2, 2, 6, 6-pentamethylpiperidine, and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, and potassium hydrogen carbonate.
- the solvent used in this production method may be any solvent as long as it is inert in the reaction itself and does not inhibit the reaction. Examples thereof include halogens such as dichloromethane, 1,2-dichloroethane, and chloroform.
- Hydrocarbon solvents aromatic hydrocarbon solvents such as benzene and toluene, acetone, acetonitrile, N, N-dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, tetramethylene sulfolane, tetramethylene sulfoxide
- Xamethylene phosphoryl Aprotic polar solvents such as lactotriamide; ester solvents such as methyl acetate and ethyl acetate; ether solvents such as tetrahydrofuran, getyl ether and 1,4-dioxane; and organic solvents such as pyridine, picoline, lutidine and collidine.
- a basic solvent or a mixed solvent thereof can be used. The reaction is carried out in a range from ice-cooling to 200.
- R and R 1 have the same meanings as described above, and Ac represents an acetyl group.
- R 6 is a hydrogen atom, an alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, a (cycloalkyl) alkyl group which may have a substituent, Represents an aryl group which may have a substituent or an aralkyl group which may have a substituent, and W represents an acid anhydride residue.
- R 7 is a hydrogen atom, an alkyl group which may have a substituent, a cycloalkyl group which may have a substituent, a (cycloalkyl) alkyl group which may have a substituent, Having an aryl group which may have a substituent, an aralkyl group which may have a substituent, an alkoxy group which may have a substituent, an aryloxy group which may have a substituent or a substituent Represents an aralkyloxy group, and Q represents a halogen atom.
- R 8 represents an alkyl group which may have a substituent, an aryl group which may have a substituent, or an aralkyl group which may have a substituent.
- Examples of the base used in the present production method include, for example, triethylamine, pyridine, N, N-diisopropylethylamine, 4-dimethylaminopyridine, 1,8-diazabicyclo [5.4.0] —7— Organic bases such as pendecene, 1, 2, 2, 6, 6-pentamethylpiperidine, and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, and potassium hydrogen carbonate.
- the solvent used in this production method may be any solvent as long as it is inert in the reaction itself and does not inhibit the reaction. Examples thereof include halogens such as dichloromethane, 1,2-dichloroethane, and chloroform.
- Hydrocarbon solvents aromatic hydrocarbon solvents such as benzene and toluene, acetone, acetonitrile, N, N-dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, tetramethylene sulfolane, tetramethylene sulfoxide , Aprotic polar solvents such as hexamethylenephosphoric triamide, ester solvents such as methyl acetate and ethyl acetate, ether solvents such as tetrahydrofuran, geethyl ether, 1,4-dioxane, pyridine, picoline, Organic bases such as lutidine and collidine Nakadachimata the mixed solvents thereof.
- the reaction is carried out in a range from ice-cooling to 200.
- R 1 has the same meaning as described above, and T represents a halogen atom, a mesyloxy group, a trisoxy group or a trifluoromethylsulfonyloxy group.
- tetrabutylammonium iodide can be produced in the presence or absence of sodium iodide or a base in the absence or presence of a solvent.
- the base used in the present production method for example, triethylamine, pyridine, N, N-diisopropylethylamine, 4-dimethylaminopyridine, 1,8-diazabicyclo [5.4.0] —7—
- Organic bases such as dendecene, 1, 2, 2, 6, 6-pentamethylpiperidine, or sodium carbonate, potassium carbonate, sodium hydrogencarbonate, sodium hydrogencarbonate, sodium hydride, sodium hydroxide, potassium hydroxide, etc.
- the solvent used may be any solvent as long as it is inert in the reaction itself and does not inhibit the reaction.
- a halogen such as dichloromethane, 1,2-dichloroethane, and chloroform are used.
- Hydrocarbon solvents aromatic hydrocarbon solvents such as benzene and toluene, acetone, acetonitrile, N, N-dimethylformamide, N-methyl-2-pyrrolid Aprotic polar solvents such as don, dimethylsulfoxide, tetramethylenesulfolane, tetramethylenesulfoxide, hexamethylenephosphoric triamide, ester solvents such as methyl acetate, ethyl acetate, etc., tetrahydrofuran, getyl ether, 1, 41
- ether solvents such as dioxane
- organic base solvents such as pyridine, picoline, lutidin and collidine
- mixed solvents thereof The reaction is carried out in a range from ice-cooling to 200.
- the compound wherein R 1 is a cycloalkyl group substituted with an alkoxy group is represented by the general formula (VI) II) and a compound represented by the following general formula (X)
- R 9 and R IQ each independently represent an alkoxy group, and m represents an integer of 1 to 4.
- R 11 represents an alkoxy group, and k represents an integer of 1 to 4.
- Examples of the acid used in the present production method include pyridine hydrochloride, pyridin trifluoroacetate, pyridine P-toluenesulfonate and the like.
- the solvent used is itself inert in the reaction, Any solvent may be used as long as it does not hinder the reaction.
- halogenated hydrocarbon solvents such as dichloromethane, 1,2-dichloroethane, and chloroform
- aromatic solvents such as benzene and toluene.
- Non-protons such as aromatic hydrocarbon solvents, acetone, acetonitrile, N, N-dimethylformamide, N-methyl-2-pyrrolidone, dimethylsulfoxide, tetramethylenesulfolane, tetramethylenesulfoxide, hexamethylenephosphoric triamide
- Examples include a polar solvent, an ester solvent such as methyl acetate and ethyl acetate, an ether solvent such as tetrahydrofuran, getyl ether, 1,4-dioxane, and a mixed solvent thereof.
- the reaction is carried out in a range from ice-cooling to 200.
- those compounds in which R 2 is a hydrogen atom are those wherein R 2 is acetyl in the above general formula (I)
- the compound can be produced by hydrolyzing the compound as a group without a solvent or in a solvent in the presence or absence of an acid or a base.
- Examples of the acid used in the present production method include hydrochloric acid and sulfuric acid.
- Examples of the base used include sodium hydrogen carbonate, sodium carbonate, sodium hydroxide, lithium hydroxide, barium hydroxide, Examples include methoxy sodium, ethoxy sodium, tert-butoxy sodium, and tert-butoxy potassium.
- These acids or alcohols can be used as aqueous solutions, but alcoholic solvents such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, sec-butyl alcohol, tert-butyl alcohol, etc.
- Aprotic polar solvents such as acetone, acetone, acetonitrile, N, N-dimethylformamide, dimethylsulfoxide, tetramethylenesulfolane, tetramethylenesulfoxide, hexamethylenephosphoric triamide; tetrahydrofuran; It can be used as a solution of an ether-based solvent such as dioxane or a hydrated solvent thereof. The reaction is carried out in a range from ice-cooling to 200.
- R and R 1 have the same meanings as described above, and Ac represents an acetyl group.
- R 2 and R 3 have the same meanings as described above, and R 12 represents an alkyl group having 2 to 4 carbon atoms which may have a substituent.
- compositions containing at least one novel erythromycin derivative represented by the above general formula (I) or a physiologically acceptable salt thereof as an active ingredient produced in this manner are usually capsules, tablets, tablets, It is administered as an oral preparation such as fine granules, granules, powders and syrups, or as an injection, suppository, eye drops, eye ointment, ear drops, nasal drops or skin preparation.
- oral preparation such as fine granules, granules, powders and syrups, or as an injection, suppository, eye drops, eye ointment, ear drops, nasal drops or skin preparation.
- These preparations can be manufactured by a conventional method by adding physiologically and pharmaceutically acceptable additives.
- Excipients lactose, sucrose, D-mannitol, corn starch, crystalline cell mouth, etc.
- disintegrants carboxymethylcellulose potassium, partially alpha starch, croscarmellose sodium, crospopidone, etc.
- Binders hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, etc.
- lubricants magnesium stearate, talc, hydrogenated oil, dimethylpolysiloxane, hydrated silicon dioxide, light silica anhydride, carnauba wax, etc.
- Coating agents hydroxypropylmethylcellulose, sucrose, titanium oxide, etc.
- plasticizers triethyl citrate, polyethylene daricol, glycerin fatty acid esters, etc.
- base materials polyethylene glycol, etc.
- a drug containing the compound of the present invention as an active ingredient when administered to a patient, it depends on the patient's condition.In general, for an adult, the daily dose is about 10 to 200 mg orally as a daily dose, non-oral About 1 to 100 mg can be administered once or several times a day. However, it is desirable to increase or decrease as appropriate according to the purpose of treatment or prevention, the site of infection and the type of pathogenic bacteria, the age and symptoms of the patient, and the like.
- Me is a methyl group
- Et is an ethyl group
- n-Pr is an n-propyl group
- i-Pr is an isopropyl group
- n-Bu is an n-butyl group
- n-Hex is n-hexyl.
- n-Oct is n-octyl group
- n-Dodec is ⁇ -dodecyl group
- Ac is acetyl group
- the description in Kazuko in the property item indicates recrystallization solvent.
- Erythromycin A 9 [0- (3-phenoxypropyl) oxime] Erythromycin A 9—oxime 4.0 g, tetrabutylammonium iodide 0.10 g, sodium iodide 0.12
- a mixed solution of 1.3 g of g-brominated 3-phenoxypropyl and 40 ml of tetrahydrofuran was added 0.43 g of powdered lithium hydroxide with stirring at room temperature, and the mixture was stirred at room temperature for 16.5 hours. .
- the reaction solution was concentrated under reduced pressure, and a saturated aqueous sodium hydrogen carbonate solution was added to the obtained residue to make the solution viscous, followed by extraction with ethyl acetate.
- the extract was washed with water, washed with saturated saline, dried over sodium sulfate, and the solvent was removed under reduced pressure.
- the residue was solidified by adding getyl ether and diisopropyl ether to obtain 2.80 g of a colorless solid.
- Example 54 In the same manner as in Example 54, the compounds of Examples 55 to 108 were obtained.
- Example 71 0.90 g of the colorless amorphous solid obtained in Example 71 was crystallized from n-heptane to obtain 0.47 g of colorless crystals having a melting point of 130 to 132.5. This compound was identical in NMR spectrum to the compound obtained in Example 71.
- control compounds were clarithromycin and Rifampicin and 4 "-acetyl erythromycin A 9-(-methyl methyl oxime) (compound described in JP-A-63-107921) were used.
- Ac represents an acetyl group. Represent.
- Control compound 3 Antibacterial activity against atypical mycobacteria
- the antibacterial activity (minimum inhibitory concentration) of the clinical isolates against atypical mycobacteria was measured by an agar plate dilution method (according to the standard method of the Japan Society for Chemotherapy). That, 1 0 6 CFU / ml to the adjusted bacterial suspension (approximately 5 zl) was spotted on the drug-containing 7 H 1 1 agar on, 3 7 "C, 7 days Minimal presence or absence of bacterial growth after incubation The inhibitory concentration was determined, and the results are shown in the following table: The compound of the present invention inhibits clarithromycin-resistant atypical mycobacteria (such as M. avium 20092). It showed superior antibacterial activity against the atypical mycobacteria included in comparison with the control compound.
- the names of the bacteria in the table are as follows.
- Mycobacterium avium (M. avium)
- Mycobacterium intracel lulare (M. intracel lulare) antibacterial activity (minimum inhibitory concentration g / ml)
- novel erythromycin derivative or its salt according to the present invention has excellent antibacterial activity against atypical mycobacteria including multidrug-resistant bacteria, and is extremely useful as an antibacterial agent.
- R represents a hydrogen atom or a lower alkyl group, represents an alkyl group having 5 to 12 carbon atoms which may have a substituent, a cycloalkyl group which may have a substituent, and a group having a substituent.
- R 2 is a hydrogen atom or an acetyl group
- R 4 represents an optionally substituted alkyl group
- R 5 represents an aralkyl group which may have a substituent;
- R 5 represents an aralkyl group which may have a substituent;
- An erythromycin derivative represented by the formula or a salt thereof is an erythromycin derivative represented by the formula or a salt thereof.
- R 1 is an alkyl group having 5 to 12 carbon atoms which may have a substituent, a cycloalkyl group which may have a substituent or a cycloalkyl group which may have a substituent (cycloalkyl)
- R 2 represents a hydrogen atom or an acetyl group
- R 3 represents a substituent
- An optionally substituted acyl group or a group represented by the formula —C ( 0) —Y—R 5 , wherein R 4 is an optionally substituted alkyl group or an optionally substituted substituent Alkoxyalkyl group, alkylthioalkyl group which may have a substituent, alkylaminoalkyl group which may have a substituent, aryl group which may have a substituent, and aralkyl
- n represents an integer of 1 to 6
- X represents an oxygen atom, a sulfur atom or a group represented by 1 NZ—
- Y represents an oxygen atom or a group represented by —NH—
- Z represents a hydrogen atom or an alkyl group which may have a substituent.
- An erythromycin derivative represented by the formula or a salt thereof is an erythromycin derivative represented by the formula or a salt thereof.
- R 2 is a hydrogen atom, or a salt thereof.
- a medicament comprising, as an active ingredient, the compound according to any one of claims 1 to 3 or a physiologically acceptable salt thereof.
- An antibacterial agent comprising the compound according to any one of claims 1 to 3 or a physiologically acceptable salt thereof as an active ingredient.
- a remedy for atypical mycobacterial infection comprising the compound according to any one of claims 1 to 3 or a physiologically acceptable salt thereof as an active ingredient.
- a method for treating an infectious disease wherein a therapeutically effective amount of the compound according to any one of claims 1 to 3 or a physiologically acceptable salt thereof is a mammal, including a human. And administering to the subject.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36710/00A AU3671000A (en) | 1999-04-08 | 2000-04-06 | Erythromycin derivatives |
IL14525600A IL145256A0 (en) | 1999-04-08 | 2000-04-06 | Erythromycin derivatives |
PL00354409A PL354409A1 (en) | 1999-04-08 | 2000-04-06 | Erythromycin derivatives |
EP20000915372 EP1167375A4 (en) | 1999-04-08 | 2000-04-06 | ERYTHROMYCIN DERIVATIVES |
CA002367319A CA2367319A1 (en) | 1999-04-08 | 2000-04-06 | Erythromycin derivatives |
BR0010518-0A BR0010518A (pt) | 1999-04-08 | 2000-04-06 | Derivados da eritromicina |
KR1020017011771A KR20020007333A (ko) | 1999-04-08 | 2000-04-06 | 에리스로마이신 유도체 |
SK1397-2001A SK13972001A3 (sk) | 1999-04-08 | 2000-04-06 | Erytromycínové deriváty |
NO20014362A NO20014362L (no) | 1999-04-08 | 2001-09-07 | Erytromycinderivater |
BG105919A BG105919A (en) | 1999-04-08 | 2001-09-19 | Erythromycin derivatives |
HK02107210.7A HK1045697A1 (zh) | 1999-04-08 | 2002-09-30 | 紅霉素衍生物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/100726 | 1999-04-08 | ||
JP10072699 | 1999-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000061593A1 true WO2000061593A1 (fr) | 2000-10-19 |
Family
ID=14281635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/002226 WO2000061593A1 (fr) | 1999-04-08 | 2000-04-06 | Derives d'erythromycine |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1167375A4 (ja) |
KR (1) | KR20020007333A (ja) |
CN (1) | CN1343216A (ja) |
AR (1) | AR023264A1 (ja) |
AU (1) | AU3671000A (ja) |
BG (1) | BG105919A (ja) |
BR (1) | BR0010518A (ja) |
CA (1) | CA2367319A1 (ja) |
CZ (1) | CZ20013497A3 (ja) |
HK (1) | HK1045697A1 (ja) |
HU (1) | HUP0201116A3 (ja) |
IL (1) | IL145256A0 (ja) |
NO (1) | NO20014362L (ja) |
NZ (1) | NZ513998A (ja) |
PL (1) | PL354409A1 (ja) |
SK (1) | SK13972001A3 (ja) |
TR (1) | TR200102572T2 (ja) |
WO (1) | WO2000061593A1 (ja) |
ZA (1) | ZA200107346B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026753A1 (fr) * | 2000-09-27 | 2002-04-04 | Hokuriku Seiyaku Co.,Ltd. | Dérivés d'érythromycine et médicaments en contenant |
WO2001063539A3 (en) * | 2000-02-24 | 2003-03-06 | Abbott Lab | Anti-infective agents useful against multidrug-resistant strains of bacteria |
WO2003022289A1 (fr) * | 2001-09-05 | 2003-03-20 | Hokuriku Seiyaku Co., Ltd. | Medicament contenant de l'erythromycine pour traiter ou prevenir la tuberculose |
US6946446B2 (en) | 2000-02-24 | 2005-09-20 | Abbott Laboratories | Anti-infective agents useful against multidrug-resistant strains of bacteria |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2801100A1 (en) | 2003-03-10 | 2004-09-23 | Optimer Pharmaceuticals, Inc. | Macrolides and processes for their preparation |
WO2004108744A2 (en) * | 2003-05-19 | 2004-12-16 | Prasad K Deshpande | Azalides and azaketolides having antimicrobial activity |
WO2006120541A1 (en) | 2005-05-10 | 2006-11-16 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Ether linked macrolides useful for the treatment of microbial infections |
CN105732745A (zh) | 2007-10-25 | 2016-07-06 | 森普拉制药公司 | 大环内酯类抗菌剂的制备方法 |
CN107854477A (zh) | 2008-10-24 | 2018-03-30 | 森普拉制药公司 | 使用含***的大环内酯治疗抗性疾病的方法 |
US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
WO2011032052A1 (en) | 2009-09-10 | 2011-03-17 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and mac diseases |
PL2571506T3 (pl) * | 2010-05-20 | 2017-10-31 | Cempra Pharmaceuticals Inc | Sposoby sporządzania makrolidów i ketolidów oraz ich produktów pośrednich |
KR20180110181A (ko) | 2010-09-10 | 2018-10-08 | 셈프라 파마슈티컬스, 인크. | 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드 |
IN2014DN08939A (ja) | 2012-03-27 | 2015-05-22 | Cempra Pharmaceuticals Inc | |
AU2014239959A1 (en) | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
EP2968384A4 (en) | 2013-03-15 | 2017-02-15 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
AU2014252462A1 (en) * | 2013-04-10 | 2015-10-01 | Probiotic Pharmaceuticals Aps | Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0422843A2 (en) * | 1989-10-07 | 1991-04-17 | Taisho Pharmaceutical Co. Ltd | 6-0 Methylerythromycin A oxime derivatives |
EP0895999A1 (en) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8506380D0 (en) * | 1985-03-12 | 1985-04-11 | Beecham Group Plc | Chemical compounds |
DE3668894D1 (en) * | 1985-03-12 | 1990-03-15 | Beecham Group Plc | Erythromycin-derivate. |
US5719272A (en) * | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
-
2000
- 2000-04-05 AR ARP000101551A patent/AR023264A1/es unknown
- 2000-04-06 NZ NZ513998A patent/NZ513998A/xx not_active Application Discontinuation
- 2000-04-06 BR BR0010518-0A patent/BR0010518A/pt not_active IP Right Cessation
- 2000-04-06 IL IL14525600A patent/IL145256A0/xx unknown
- 2000-04-06 PL PL00354409A patent/PL354409A1/xx unknown
- 2000-04-06 WO PCT/JP2000/002226 patent/WO2000061593A1/ja active Application Filing
- 2000-04-06 CA CA002367319A patent/CA2367319A1/en not_active Abandoned
- 2000-04-06 AU AU36710/00A patent/AU3671000A/en not_active Abandoned
- 2000-04-06 TR TR2001/02572T patent/TR200102572T2/xx unknown
- 2000-04-06 CN CN00805014A patent/CN1343216A/zh active Pending
- 2000-04-06 KR KR1020017011771A patent/KR20020007333A/ko not_active Application Discontinuation
- 2000-04-06 SK SK1397-2001A patent/SK13972001A3/sk unknown
- 2000-04-06 HU HU0201116A patent/HUP0201116A3/hu unknown
- 2000-04-06 EP EP20000915372 patent/EP1167375A4/en not_active Withdrawn
- 2000-04-06 CZ CZ20013497A patent/CZ20013497A3/cs unknown
-
2001
- 2001-09-05 ZA ZA200107346A patent/ZA200107346B/xx unknown
- 2001-09-07 NO NO20014362A patent/NO20014362L/no not_active Application Discontinuation
- 2001-09-19 BG BG105919A patent/BG105919A/xx unknown
-
2002
- 2002-09-30 HK HK02107210.7A patent/HK1045697A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0422843A2 (en) * | 1989-10-07 | 1991-04-17 | Taisho Pharmaceutical Co. Ltd | 6-0 Methylerythromycin A oxime derivatives |
EP0895999A1 (en) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
Non-Patent Citations (1)
Title |
---|
See also references of EP1167375A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001063539A3 (en) * | 2000-02-24 | 2003-03-06 | Abbott Lab | Anti-infective agents useful against multidrug-resistant strains of bacteria |
US6946446B2 (en) | 2000-02-24 | 2005-09-20 | Abbott Laboratories | Anti-infective agents useful against multidrug-resistant strains of bacteria |
WO2002026753A1 (fr) * | 2000-09-27 | 2002-04-04 | Hokuriku Seiyaku Co.,Ltd. | Dérivés d'érythromycine et médicaments en contenant |
WO2003022289A1 (fr) * | 2001-09-05 | 2003-03-20 | Hokuriku Seiyaku Co., Ltd. | Medicament contenant de l'erythromycine pour traiter ou prevenir la tuberculose |
Also Published As
Publication number | Publication date |
---|---|
NO20014362D0 (no) | 2001-09-07 |
HK1045697A1 (zh) | 2002-12-06 |
NO20014362L (no) | 2001-12-04 |
BR0010518A (pt) | 2002-01-08 |
SK13972001A3 (sk) | 2002-08-06 |
ZA200107346B (en) | 2002-11-27 |
AU3671000A (en) | 2000-11-14 |
HUP0201116A3 (en) | 2003-03-28 |
IL145256A0 (en) | 2002-06-30 |
CZ20013497A3 (cs) | 2002-05-15 |
HUP0201116A2 (en) | 2002-08-28 |
NZ513998A (en) | 2001-09-28 |
TR200102572T2 (tr) | 2002-02-21 |
EP1167375A4 (en) | 2002-10-30 |
PL354409A1 (en) | 2004-01-12 |
CA2367319A1 (en) | 2000-10-19 |
KR20020007333A (ko) | 2002-01-26 |
AR023264A1 (es) | 2002-09-04 |
CN1343216A (zh) | 2002-04-03 |
EP1167375A1 (en) | 2002-01-02 |
BG105919A (en) | 2002-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2535174B2 (ja) | 半合成エリスロマイシン抗生物質 | |
WO2000061593A1 (fr) | Derives d'erythromycine | |
TWI243824B (en) | 13-membered azalides and their use as antibiotic agents | |
KR19990067492A (ko) | 트리사이클릭 에리트로마이신 유도체 | |
CA2301643A1 (en) | 6,9-bridged erythromycin derivatives | |
WO2005007143A2 (en) | Use of makrolides and ketolides for the treatment of tuberculosis | |
JP2000351794A (ja) | エリスロマイシン誘導体 | |
JP6890865B1 (ja) | 狂犬病治療のための環状アミド化合物およびその方法 | |
US6436906B1 (en) | 9-amino-14-membered macrolides derived from leucomycins | |
CN105524132B (zh) | 含有喹啉取代基的红霉素a酮内酯类抗生素衍生物、其制备方法及应用 | |
WO1994021657A1 (en) | Antibacterial 16-membered ring macrolides containing olefins at c-20 | |
EP1044985A1 (en) | Erythromycin derivatives | |
JP2002173498A (ja) | エリスロマイシン誘導体 | |
MXPA01009306A (es) | Derivados de eritromicina | |
JPWO2005073238A1 (ja) | ピリドベンズオキサジン誘導体 | |
EP1259923B1 (en) | Anti-infective agents useful against mulitidrug-resistant strains of bacteria | |
JPH11236395A (ja) | エリスロマイシン誘導体 | |
EP3522896A2 (en) | Ketolides having antibacterial activity | |
JP2000351793A (ja) | エリスロマイシン誘導体 | |
JP2003073394A (ja) | エリスロマイシン誘導体 | |
CA3198475A1 (en) | Novel compound, preparation method thereof, and antibiotic composition comprising same | |
US20040006027A1 (en) | 11-C-substituted derivatives of clarithromycin | |
JP2001181294A (ja) | エリスロマイシン誘導体 | |
JP2003155241A (ja) | エリスロマイシン誘導体を含有する結核の治療又は予防のための医薬 | |
JPH08104638A (ja) | Il−5産生抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00805014.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000915372 Country of ref document: EP Ref document number: 36710/00 Country of ref document: AU Ref document number: 2001/02572 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 513998 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09926118 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2367319 Country of ref document: CA Ref document number: 2367319 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/1250/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/009306 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017011771 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 105919 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-3497 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13972001 Country of ref document: SK |
|
WWP | Wipo information: published in national office |
Ref document number: 2000915372 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017011771 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-3497 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000915372 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017011771 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-3497 Country of ref document: CZ |